Fusion genes or chromosomal rearrangements are somatic alterations in cancer while, hematological cancer, sarcomas, ovarian cancer and prostate cancer are all result of fusion genes. The detection of fusion genes has become an important in prognostic and diagnostic biomarker and for biopharmaceutical development. 

Growing prevalence of cancer diseases across globe have become major contribution in target market growth. Further, continuous research & development activities in cancer screening and prevention is likely to propel the demand for target market growth. Furthermore, leveraging artificial intelligence (AI) technology in prediction of gene fusion status in various types of cancer is expected to provide lucrative opportunities in target market growth over the forecast period.

The report “Gene Fusion Testing Market, By Indication (Hematological Malignancies, Solid Tumors), By Technology (FISH, NGS, PCR, IHC), By End-Users (Hospitals, Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Academic & Research Centers), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032”

 Key Highlights:

• In May 2020, Bayer and NeoGenomics launched new ‘Test4TRK’ gene fusion testing program with free of cost for patients with metastatic colorectal cancer and RAI-refractory differentiated thyroid cancer. This testing program covered the Bayers cost of testing for up to 500 patients in United States.

Analyst View:

Growing utilization of gene fusion testing in targeted therapies has driven the demand for target market growth. Technological advancement and emerging AI technology in cancer screening is anticipated to increase demand for Gene Fusion Testing market growth. As a result, market competition is intensifying, and both big international corporations and start-ups are vying to establish position in the market.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on

“Gene Fusion Testing Market, By Indication (Hematological Malignancies, Solid Tumors), By Technology (FISH, NGS, PCR, IHC), By End-Users (Hospitals, Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Academic & Research Centers), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032”

Key Market Insights from the report:

Gene Fusion Testing Market accounted for US$ 255.3 million in 2022 and is estimated to be US$ 794.0 million by 2032 and is anticipated to register a CAGR of 12.5%. The Gene Fusion Testing Market is segmented based on Indication, Technology, End-Users and Region.

• Based on Indication, Gene Fusion Testing Market is segmented into Hematological Malignancies, Solid Tumors.
• Based on Technology, Gene Fusion Testing Market is segmented into FISH (Fluorescence in Situ Hybridization), NGS (Next-Generation Sequencing), PCR (Polymerase Chain Reaction), IHC (Immunohistochemistry).
• Based on End-Users, Gene Fusion Testing Market is segmented into Hospitals, Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Academic & Research Centers.
• By Region, the Gene Fusion Testing Market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East & Africa.

Competitive Landscape & their strategies of Gene Fusion Testing Market:

The prominent players operating in the Gene Fusion Testing Market includes, Amoy Diagnostics Co. Ltd., Arima Genomics, F. Hoffman-La Roche Ltd., ArcherDX, Biocartis, Illumina, Danaher Corporation, Guardant Health, Biocare Medical LLC., and Myriad Genetics Inc.

To know more

Contact Us:

Sales

Prophecy Market Insights

 U.S.  1 860 531 2574

RoW: 917775049802

Email- sales@prophecymarketinsights.com

Website- www.prophecymarketinsights.com

Blog- www.prophecyjournals.com